- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03. | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 229 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen | |
| 15.10.24 | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 325 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,462 | +5,53 % | Sangamo Therapeutics falls on CFO retirement | ||
| IMMATICS | 5,400 | +5,88 % | Immatics Announces Second Quarter 2025 Financial Results and Business Update | Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated... ► Artikel lesen | |
| ALDEYRA | 4,103 | -0,89 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
| MEDIFAST | 11,960 | +0,04 % | Medifast Bolsters Growth Through Health & Wellness Solutions | ||
| PHARMING | 1,194 | -2,37 % | Pharming Group N.V.: Pharming Group promoted to the Euronext AMX index | Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,176 | +2,57 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 14,100 | +2,92 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 | Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 2,420 | -4,72 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update | Entered into secured credit agreement with Innoviva for $15 million maturing in 2029
Announced positive topline results from the Phase 1b /2a diSArm trial for AP-SA02
... ► Artikel lesen | |
| INNOVIVA | 16,300 | +0,62 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
| DBV TECHNOLOGIES | 1,640 | +1,74 % | DBV Technologies stock rating reiterated at Market Outperform by JMP | ||
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update | Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025
NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,660 | 0,00 % | SIGA To Appeal $1.175 Million FINTRAC Fine | ||
| LIQUIDIA | 22,160 | +4,82 % | Liquidia Corporation (LQDA): A Bull Case Theory | ||
| SYNDAX PHARMACEUTICALS | 12,600 | +0,80 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September... ► Artikel lesen | |
| MATINAS BIOPHARMA | 1,685 | 0,00 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report |
Das Unternehmen MOLECURE SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,712 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.